Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Transactions
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Dividend declared
Quarterly results
Credit agrmnt [a]
Director departure
Appointed director
CC transcript
Asset disposition
Inv. presentation
ALLERGAN INC (AGN) Create: Alert

All | News | Filings
Date FiledTypeDescription
03/18/2015 8-K Quarterly results
03/11/2015 8-K Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits
Docs: "Actavis and Allergan Shareholders Approve Proposals Related to Actavis' Planned Acquisition of Allergan DUBLIN, Ireland & IRVINE, Calif. - March 10, 2015 - Actavis plc and Allergan, Inc. announced that, at shareholder meetings held today, all proposals related to Actavis' planned acquisition of Allergan were approved by both Actavis' and Allergan's shareholders. Actavis' and Allergan's shareholder approvals satisfy certain conditions to the closing of the transaction. The closing of the transaction is expected to occur late in the first quarter or early in the second quarter of 2015, subject to the satisfaction or waiver of certain regulatory approvals and other customary closing conditions. 1 About Actavis About Actavis plc , headquartered in Dublin, Ireland, is a unique specialty pharmac..."
02/04/2015 8-K Quarterly results
Docs: "ALLERGAN REPORTS FOURTH QUARTER 2014 OPERATING RESULTS"
01/12/2015 8-K Other Events, Financial Statements and Exhibits
Docs: "Actavis and Allergan Announce Early Termination of Hart-Scott-Rodino Waiting Period for Actavis' Pending Acquisition of Allergan and Record Dates for Shareholder Meetings"
12/01/2014 8-K Other Events
11/18/2014 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits
Docs: "Agreement and Plan of Merger, by and among Actavis plc, Avocado Acquisition Inc. and Allergan, Inc",
"Employee communication"
11/12/2014 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits
Docs: "Allergan, Inc. Amended and Restated Bylaws",
"Marked Bylaws of Allergan, Inc",
"Allergan Board of Directors Announces Approval of Amendments to Company's Bylaws"
10/27/2014 8-K Asset disposition
Docs: "Allergan, Inc. investor presentation"
10/27/2014 8-K Quarterly results
Docs: "ALLERGAN REPORTS THIRD QUARTER 2014 OPERATING RESULTS"
10/17/2014 8-K Asset disposition
Docs: "Allergan, Inc. investor presentation"
10/09/2014 8-K Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits
Docs: "ALLERGAN PROVIDES UPDATE ON EARNINGS PER SHARE AND SALES EXPECTATIONS - Allergan, Inc. today provided the following updates on earnings per share and sales expectations based on current information. Third Quarter 2014"
09/29/2014 8-K Investor presentation
Docs: "Allergan, Inc. investor presentation"
09/29/2014 8-K Other Events, Financial Statements and Exhibits
Docs: "ALLERGAN BOARD OF DIRECTORS ISSUES STATEMENT",
"Allergan Announces FDA Approves Revised Indication of OZURDEX ® for the Treatment of Diabetic Macular Edema"
08/22/2014 8-K Other Events
08/18/2014 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Allergan Names Jim Hindman Chief Financial Officer"
07/23/2014 8-K Other Events
07/21/2014 8-K Quarterly results
Docs: "ALLERGAN REPORTS SECOND QUARTER 2014 OPERATING RESULTS",
"Allergan, Inc. investor presentation",
"Letter from Allergan, Inc. to its employees",
"Letter from Allergan, Inc. to its customers"
07/14/2014 8-K Asset disposition, Investor presentation
Docs: "Allergan, Inc. investor presentation",
"ALLERGAN FILES INVESTOR PRESENTATION"
07/11/2014 8-K Other Events, Financial Statements and Exhibits
Docs: "Allergan Comments on Pershing Square's Definitive Proxy Solicitation"
06/30/2014 8-K Investor presentation
Docs: "Allergan, Inc. CVR presentation"
06/30/2014 8-K Investor presentation
Docs: "ALLERGAN ANNOUNCES R&D PIPELINE UPDATE AND U.S. FDA APPROVAL Company to Host Conference Call Today, Monday, June 30th at 10:30 AM ET",
"Allergan, Inc. research and development update presentation"
06/27/2014 8-K Other Events
06/10/2014 8-K Other Events, Financial Statements and Exhibits
Docs: "Allergan Board Unanimously Rejects Revised Unsolicited Proposal from Valeant",
"Allergan, Inc. investor presentation",
"Letter from Allergan, Inc. to its employees",
"Letter from Allergan, Inc. to its customers"
06/02/2014 8-K Other Events, Financial Statements and Exhibits
Docs: "Allergan Comments on Pershing Square's and Valeant's Attempt to Remove a Majority of the Members of the Allergan Board of Directors"
05/30/2014 8-K Other Events, Financial Statements and Exhibits
Docs: "Allergan Acknowledges Revised, Unsolicited Proposal from Valeant and Pershing Square"
05/28/2014 8-K Other Events, Financial Statements and Exhibits
Docs: "Allergan Confirms Receipt of Revised, Unsolicited Proposal from Valeant"
05/27/2014 8-K Investor presentation
Docs: "Allergan Files Investor Presentation Detailing Concerns About the Sustainability of Valeant's Business Model",
"Allergan, Inc. investor presentation"
05/21/2014 8-K Other Events, Financial Statements and Exhibits
Docs: "Letter from Mr. Gallagher to Pershing Square Capital Management, L.P"
05/19/2014 8-K Other Events, Financial Statements and Exhibits
Docs: "Letter from Mr. Gallagher to Pershing Square Capital Management, L.P",
"Letter from Allergan, Inc. to its employees"
05/12/2014 8-K Other Events, Financial Statements and Exhibits
Docs: "Allergan Board Unanimously Rejects Unsolicited Proposal from Valeant",
"Allergan, Inc. investor presentation",
"Letter from Allergan, Inc. to its employees",
"Letter from Allergan, Inc. to its customers"
05/09/2014 8-K Submission of Matters to a Vote of Security Holders
05/07/2014 8-K Quarterly results
Docs: "ALLERGAN REPORTS FIRST QUARTER 2014 OPERATING RESULTS"
04/23/2014 8-K Entry into a Material Definitive Agreement, Material Modifications to Rights of Security Holders, Amendments to Articles of I...
Docs: "Certificate of Designations of Series A Junior Participating Preferred Stock of Allergan, Inc. filed with the Secretary of State of the State of Delaware on April 23, 2014",
"Rights Agreement, between Allergan, Inc. and Wells Fargo Bank, N.A., which includes the form of Certificate of Designations of Preferred Stock as Exhibit A, the form of Right Certificate as Exhibit B, and the Summary of Rights to Purchase Preferred Stock as Exhibit C",
"Allergan Adopts One-Year Stockholder Rights Plan"
03/13/2014 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy